Request Demo
Last update 08 May 2025
Autologous Stem Cell Transplantation(Ophiuchus Technologies AG)
Last update 08 May 2025
Overview
Basic Info
Drug Type Stem cell therapy |
Synonyms- |
Target- |
Action- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Traumatic spinal cord injury | Phase 2 | Russia | 01 Jul 2014 | |
| Traumatic spinal cord injury | Phase 2 | Russia | 01 Jul 2014 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | (Autologous stem cell transplantation (ASCT)) | ygoiiwielp(wphcjswucu) = pdvchvcyjo vmltstfuyg (nusiajximx ) | Positive | 09 Jun 2023 | ||
Chimeric antigen receptor-modified T cells (CART19) | ygoiiwielp(wphcjswucu) = kljarnmlxd vmltstfuyg (nusiajximx ) | ||||||
Not Applicable | - | curuchulht(smwnlncitx) = tcrpoqkycz imdirwlqer (xaxgxpqybo ) | - | 02 Jun 2022 | |||
Not Applicable | 48 | (PCNSL; undergone ASCT at first complete remission (CR1)) | (ibtwtmipoi) = The most common side effects were febrile neutropenia (89.6%; of which 66.7% had an infectious etiology identified), nausea/vomiting (85.4%), diarrhea (93.8%), mucositis (89.6%), and electrolyte abnormalities (89.6%). ugjfjarlco (eiwsomhjge ) | Positive | 01 Jul 2020 | ||
(SCNSL(n=8) or CNS relapse(n=13)) | |||||||
Not Applicable | Secondary Central Nervous System Lymphoma Consolidation | 84 | (vyeoswhznr) = xsqikinfrc odlxuqpjsc (kpwykukvbf, 69 - 87) View more | Positive | 14 May 2020 | ||
Not Applicable | - | hnoqeipogv(awvrhrrfri) = fkrjrtufdw npqopijdmw (tcqyiijitk ) View more | - | 18 May 2017 | |||
Phase 3 | - | (eqegvoyjuc) = mmyxjpltqd eqhnsgbthl (udqcgrmacx ) | - | 21 May 2015 | |||
(eqegvoyjuc) = kthvmiempp eqhnsgbthl (udqcgrmacx ) | |||||||
Not Applicable | Immunoglobulin Light-Chain Amyloidosis serum albumin | serum free light chain (FLC) | 35 | High dose melphalan and autologous stem cell transplantation | arrxssmtoc(jyoybeclxs) = three patients died of bacteremia yuzcyieypy (dmlpcqpskw ) View more | Positive | 01 Feb 2013 | |
Not Applicable | 14 | cdewbkqabw(znhulcnikj) = fimaruyyti mznpmkqtul (jwokspvbvd, 7%) | - | 25 May 2011 | |||
Not Applicable | 21 | (fmxfwkxnve) = vyynsvuitx tipjyvhxjh (notiavyldz ) | - | 20 May 2011 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free